MOTOVSKA, Zuzana, Ota HLINOMAZ, Petr KALA, Milan HROMADKA, Jiri KNOT, Ivo VARVAROVSKY, Jaroslav DUSEK, Jiří JARKOVSKÝ, Roman MIKLÍK, Richard ROKYTA, Frantisek TOUSEK, Petra KRAMÁRIKOVÁ, Michal SVOBODA, Bohumil MAJTAN, Stanislav SIMEK, Marian BRANNY, Jan MROZEK, Pavel CERVINKA, Jiri OSTRANSKY and Petr WIDIMSKY. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor. Journal of the American College of Cardiology. New York: Elsevier Science INC, 2018, vol. 71, No 4, p. 371-381. ISSN 0735-1097. Available from: https://dx.doi.org/10.1016/j.jacc.2017.11.008.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor
Authors MOTOVSKA, Zuzana (203 Czech Republic, guarantor), Ota HLINOMAZ (203 Czech Republic, belonging to the institution), Petr KALA (203 Czech Republic, belonging to the institution), Milan HROMADKA (203 Czech Republic), Jiri KNOT (203 Czech Republic), Ivo VARVAROVSKY (203 Czech Republic), Jaroslav DUSEK (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Roman MIKLÍK (203 Czech Republic, belonging to the institution), Richard ROKYTA (203 Czech Republic), Frantisek TOUSEK (203 Czech Republic), Petra KRAMÁRIKOVÁ (203 Czech Republic, belonging to the institution), Michal SVOBODA (203 Czech Republic, belonging to the institution), Bohumil MAJTAN (203 Czech Republic), Stanislav SIMEK (203 Czech Republic), Marian BRANNY (203 Czech Republic), Jan MROZEK (203 Czech Republic), Pavel CERVINKA (203 Czech Republic), Jiri OSTRANSKY (203 Czech Republic) and Petr WIDIMSKY (203 Czech Republic).
Edition Journal of the American College of Cardiology, New York, Elsevier Science INC, 2018, 0735-1097.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 18.639
RIV identification code RIV/00216224:14110/18:00105203
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.jacc.2017.11.008
UT WoS 000423734100001
Keywords in English myocardial infarction; outcome; prasugrel; primary percutaneous coronary intervention; switch; ticagrelor
Tags 14110115, 14110211, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 28/1/2021 11:26.
Abstract
BACKGROUND Early outcomes of patients in the PRAGUE-18 (Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction) study did not find any significant differences between 2 potent P2Y(12) inhibitors. OBJECTIVES The 1-year follow-up of the PRAGUE-18 study focused on: 1) a comparison of efficacy and safety between prasugrel and ticagrelor; and 2) the risk of major ischemic events related to an economically motivated post-discharge switch to clopidogrel. METHODS A total of 1,230 patients with acute myocardial infarction (MI) treated with primary percutaneous coronary intervention were randomized to prasugrel or ticagrelor with an intended treatment duration of 12 months. The combined endpoint was cardiovascular death, MI, or stroke at 1 year. Because patients had to cover the costs of study medication after hospital discharge, some patients decided to switch to clopidogrel. RESULTS The endpoint occurred in 6.6% of prasugrel patients and in 5.7% of ticagrelor patients (hazard ratio: 1.167; 95% confidence interval: 0.742 to 1.835; p = 0.503). No significant differences were found in: cardiovascular death (3.3% vs. 3.0%; p = 0.769), MI (3.0% vs. 2.5%; p = 0.611), stroke (1.1% vs. 0.7%; p = 0.423), all-cause death (4.7% vs. 4.2%; p = 0.654), definite stent thrombosis (1.1% vs. 1.5%; p = 0.535), all bleeding (10.9% vs. 11.1%; p = 0.999), and TIMI (Thrombolysis In Myocardial Infarction) major bleeding (0.9% vs. 0.7%; p = 0.754). The percentage of patients who switched to clopidogrel for economic reasons was 34.1% (n = 216) for prasugrel and 44.4% (n = 265) for ticagrelor (p = 0.003). Patients who were economically motivated to switch to clopidogrel had (compared with patients who continued the study medications) a lower risk of major cardiovascular events; however, they also had lower ischemic risk. CONCLUSIONS Prasugrel and ticagrelor are similarly effective during the first year after MI. Economically motivated early post-discharge switches to clopidogrel were not associated with an increased risk of ischemic events. (Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction [PRAGUE-18]; NCT02808767) (c) 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Links
LM2015090, research and development projectName: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 24/7/2024 11:26